Two more patients die in trial of Juno's JCAR015

By Gareth Macdonald

- Last updated on GMT

Two more patients die in trial of Juno's JCAR015

Related tags Leukemia

Two more patients have died during a trial of Juno Therapeutics’ candidate white blood cell cancer therapy, JCAR015.

Juno announced the deaths today, explaining that both subjects died as a result of cerebral edema, which is a swelling in the brain caused by excess fluid.

The Seattle biotech also said it has halted the trial – known as ROCKET - while it investigates the incidents.

A spokesman told us "The two patients who died earlier this week did not receive fludarabine. They were on a pre-conditioning regimen of cyclophosphamide only​."

Earlier deaths

In July​ the US FDA ordered Juno to halt the same trial following the death of three patients.

All three patients also died as a result of cerebral edema.

At the time Juno attributed the deaths to chemotherapies the patients received in addition to JCAR015, rather than to the therapy itself.

The firm was allowed to restart the trial a few days later​ after it removed one of the chemotherapeutic agents – fludarabine – from the protocol.

Rocket trial

The trial is a Phase II study examining JCAR015 in the treatment of patients suffering relapsed or refractory B cell acute lymphoblastic leukemia (ALL).

JCAR015 consists of an infusion of the patient's own T cells that have been genetically modified to express a chimeric antigen receptor (CAR) that will bind to leukemia cells that express the CD19 protein on the cell surface. 

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Related suppliers

Follow us

Products

View more

Webinars